Back to Aculeus

New Appointment - Head of Immunobiology

November 22, 2021

MELBOURNE (November 22, 2021) – Aculeus Therapeutics (“Aculeus”) is pleased to announce that Dr Geoff Matthews has been appointed as Head of Immunobiology.


Geoff brings to the role extensive experience in the pharmaceutical/biotech and academic sectors both within Australia and the United States. Geoff has expertise in cancer and molecular biology, immuno-oncology, preclinical models of cancer, epigenetics, gene editing, pre-clinical drug development, biopharma strategy and project management.


Geoff joins Aculeus from CSL where he spent 2 years as a Global R&D Project Manager following 2 years as a Strategy Consultant for Trinity Life Sciences, a biopharma consulting firm based in Boston where he provided strategic direction to leading pharmaceutical companies. Prior to that, Geoff was a Research Scientist at the Dana-Farber Cancer Institute/Harvard Medical School following a Peter Doherty Postdoctoral Research Fellowship at the Peter MacCallum Cancer Institute here in Melbourne.


Aculeus CEO Mark Devlin said “Geoff brings a deep knowledge of immunology and cancer biology to Aculeus and his appointment comes at an important time as our STING agonist development candidates enter into late preclinical phase studies”.


Welcome aboard Geoff!


About Aculeus Therapeutics


Aculeus Therapeutics is a Biotech company based in Melbourne Australia, developing small molecule drugs that modulate the immune system for the treatment of cancer and other serious diseases. Aculeus is doing this by developing drugs that target the Stimulator of Interferon Genes (STING) biochemical pathway.

Aculeus in-licensed its lead programs, STING and ENPP1, in 2020 from the CRC for Cancer Therapeutics, a Public Private Partnership between a number of Australia’s leading Medical Research Institutes, Universities and Industry partners with a track record of scientific and commercial success. Aculeus is currently advancing it’s STING agonist program through preclinical studies in preparation for formal IND-enabling studies commencing in 2022.


For more information, visit or connect with us on Twitter @AculeusTx.

Back to news